Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

The RSI reading of 29.06 for HIMS is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium ...

844-916-0895 Hims & Hers Health, Inc. (HIMS) Investigation: In the past, Hims & Hers has assured investors of its regulatory compliance, stating " [w]e are not bypassing the regulatory process [.]" ...

No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ top executives with violations of the Securities Exchange Act of 1934.

“The benefits people report most often are way more energy, better workouts and faster recovery, higher libido, clearer ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...